Previous 10 | Next 10 |
- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options - Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 - Global Phase 1/2 trial – GALax-C &...
The first patient has been dosed in Passage Bio's (PASG) Phase 1/2 clinical trial program for PBGM01 for the treatment of infantile GM1 gangliosidosis (GM1). Imagine-1 is a dose-escalation study of PBGM01 administered by a single injection into the cisterna magna in pediatric subjects with ea...
– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company – PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developin...
PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in three upcoming virtual inve...
Passage Bio (PASG) announces that it has appointed Eliseo Salinas as the company’s chief research & development ((R&D)) officer.Salinas joins the company from Acadia Pharmaceuticals, where he served as chief scientific officer ((CSO)) and senior vice presid...
PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced it has appointed Eliseo O. Salinas, M.D., MSc, as the comp...
SIOX has promising results in its gene therapy programs. Not only is the Parkinson's disease program showing impressive results, but recent developments on the rare disease front are also very encouraging. I work through these developments and then turn to the company's valuation ...
Passage Bio (PASG) announces the U.S. FDA has granted Fast Track designation to the company’s three lead investigational gene therapies: PBGM01 for the treatment of GM1 gangliosidosis ((GM1)), PBFT02 for frontotemporal dementia with granulin mutations (FTD-GRN), and PBKR03 for Krabbe d...
PHILADELPHIA, March 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the U.S. Food and Drug Administration (FDA) has granted F...
Passage Bio, Inc. (PASG) on Friday filed for a common stock offering of up to $125M.The company also filed for a mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.SEC Form S-3Passage Bio shares closed Friday up 2.1% to $...
News, Short Squeeze, Breakout and More Instantly...
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of i...